| T9529 |
TAK-020
|
1627603-21-7
|
98%
|
|
|
TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.
|
| T69980 |
XMU-MP-2
|
2031152-10-8
|
98%
|
|
|
XMU-MP-2 is a potent and selective protease inhibitor with anticancer activity that inhibits the growth of oncogenic BRK-driven tumors in a mouse xenograft model...
|
| T16702 |
QL47
|
1469988-75-7
|
98%
|
|
|
QL47 is a host-targeted small molecule antiviral agent with antiviral activity against dengue and other RNA viruses.QL47 acts as an inhibitor of viral translatio...
|
| T14692 |
BMX-IN-1
|
1431525-23-3
|
98%
|
|
|
BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine kina...
|
| T36287 |
Pirtobrutinib
|
2101700-15-4
|
98%
|
|
|
Pirtobrutinib (LOXO-305) is an advanced BTK inhibitor that displays high selectivity and operates through a non-covalent mechanism. This compound effectively inh...
|
| T60542 |
BTK-IN-16
|
2883232-92-4
|
98%
|
|
|
BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.
|
| T12152 |
N-piperidine Ibrutinib hydrochloride
|
2231747-18-3
|
98%
|
|
|
N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor, a BTK ligand, inhibits WT BTK and C481S BTK, which can be used to synthesize a range of PROTAC mo...
|
| T9705 |
TL-895
|
1415823-49-2
|
98%
|
|
|
TL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and...
|
| T73549 |
RSH-7
|
2764609-97-2
|
98%
|
|
|
RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptos...
|
| T10625 |
IBT6A
|
1022150-12-4
|
98%
|
|
|
IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
|
| T39707 |
AS-1763
|
2227211-00-7
|
98%
|
|
|
AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.
|
| T6918 |
Olmutinib
|
1353550-13-6
|
98%
|
|
|
Olmutinib (HM61713, BI 1482694) is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential ant...
|
| T4268 |
CHMFL-BMX-078
|
1808288-51-8
|
98%
|
|
|
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
|
| T3024 |
Avitinib
|
1557267-42-1
|
100%
|
|
|
Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, wi...
|
| T17220 |
Vecabrutinib
|
1510829-06-7
|
100%
|
|
|
Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.
|
| T4391 |
Syk Inhibitor II dihydrochloride
|
227449-73-2
|
100%
|
|
|
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chain...
|
| T5407 |
Branebrutinib
|
1912445-55-6
|
95.86%
|
|
|
Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC...
|
| T9408 |
N-piperidine Ibrutinib
|
330785-90-5
|
96.65%
|
|
|
N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively. N-piperidine Ibrutinib can be used as a BT...
|
| T67881 |
Acalabrutinib enantiomer
|
1952316-43-6
|
96.68%
|
|
|
Acalabrutinib enantiomer (R-Acalabrutinib) is a chemical compound that belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors. Acarabitinib enantiomer...
|
| T16157 |
MT-802
|
2231744-29-7
|
97%
|
|
|
MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
|
